Focus Prescription model
What It Covers
  • Weekly low-dose rapamycin
  • Metformin for people without diabetes
  • GLP-1 receptor agonists for weight or metabolic goals
  • Acarbose, SGLT2 inhibitors, or low-dose naltrexone in some programs
  • Baseline and periodic labs
  • Telehealth or in-person follow-up
Typical Cost $100 to $400 per month including visits
Evidence Level Early: one randomized year-long safety trial of low-dose rapamycin in healthy adults (PEARL, 115 participants) found it generally well tolerated with modest signals in women; the metformin aging trial has not completed; GLP-1 outcome data apply to obesity and diabetes, not healthy-weight adults
Regulatory Status FDA-approved drugs prescribed off-label; no drug is approved to treat aging
Watchouts
  • Prescriptions without baseline labs or a medication review
  • Dosing from an online protocol rather than trial data
  • Immune, lipid, glucose, and mouth-ulcer effects not discussed
  • Several drugs started at once
  • The clinic profits from the pharmacy that fills the prescription
Questions To Ask
  • What human trial supports this drug at this dose for someone like me?
  • What is monitored and what result would stop the prescription?
  • How does this interact with my current medications?
  • What is the plan if I get sick or need surgery while on it?
Parallel Coverage

Related Resources

This profile connects back into the article, glossary, and FAQ layers so overlapping coverage stays discoverable instead of fragmented.